1. Introduction {#sec1}
===============

As an enigmatic intracellular protein, the history of sigma (*σ*) receptor was originally categorized as an opioid receptor subtype[@bib1], and later confused with the phencyclidine (PCP) receptor due to the lack of selective ligands[@bib2]. Subsequent pharmacological studies and molecular biology have finally identified that the *σ* receptor is a non-opioid and non-PCP protein, which was at least two known subtypes, classified as sigma-1 (*σ*~1~) and sigma-2 (*σ*~2~) receptor. These two subtypes are pharmacologically similar but genetically unrelated, with different body distribution, biological function and pharmacological profiles[@bib3], [@bib4], [@bib5], [@bib6].

At present, sigma-1 receptor (*σ*~1~R) is known as a unique protein that shares no sequence homology with opioids or any other human proteins but is highly conserved across mammalian species. *σ*~1~R is a 23.5 kDa that is 223 amino acids in length[@bib5]. *σ*~1~R is widely expressed in the central nervous system (CNS) and peripheral tissues and organs[@bib7], [@bib8].

Mainly residing in the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) of cell, *σ*~1~R has been reported to interacted with numerous neurotransmitter receptors and ion channels, involved in diverse basic biochemical processes and pathological conditions related to neurodegeneration, pain sensitization, psychiatric disorders, and drug addiction[@bib7], [@bib9], [@bib10]. *σ*~1~R is also found overexpressed in many known human cancers in lung, breast, prostate, and glioma cells[@bib11], [@bib12].

The first crystal structure of human *σ*~1~R was recently solved using lipidic cubic phase (LCP) crystallography. The three-dimensional (3D) protein structure of human *σ*~1~R receptor showed a membrane-bound trimeric assembly with one transmembrane region, modifying the previous hypothesis that the receptor had two transmembrane domains[@bib13], [@bib14]. Despite the fact that structural information has only recently become available, and no endogenous ligand has been established for the receptor, numerous small molecule ligands for *σ*~1~R have been reported over the past few decades. Among these compounds, some have been developed as radiolabeled imaging tracers ([Fig. 1](#fig1){ref-type="fig"}) for positron emission tomography (PET) applications[@bib15], [@bib16], [@bib17].Figure 1Selected *σ*~1~ receptor (*σ*~1~R) ligand and radioligands.Figure 1

As a translational noninvasive imaging method, PET imaging of *σ*~1~R is a promising modality to evaluate distribution and expression in inaccessible regions and tissues. Additionally, with the specificity and selectivity radioligands, examining *σ*~1~R through PET could facilitate the investigation of *in vivo* role in pathology and progression of *σ*~1~R in different diseases directly[@bib18].

Several radiolabeled *σ*~1~R ligands have been studied in PET imaging of human investigation, but only a few of them have been used clinically. \[^11^C\]SA 4503 (**1**) is the first *σ*~1~R radioligand in human studies[@bib18]. The *ex vivo* binding assays of SA 4503 was initially reported as nanomolar affinity of *σ*~1~R (*K*~i~=4.6 nmol/L) and highly selectivity to *σ*~1~R (*σ*~2~/*σ*~1~=103)[@bib19], later the selectivity to *σ*~2~R was reinvestigated as 13.3--55.0[@bib18], [@bib20]. Besides, the low selectivity either to the emopamil binding protein (EBP) or to the vesicular acetylcholine transporter (VAChT) limited its broad use in clinic studies[@bib19], [@bib20]. There are also fluorine-18-labeled *σ*~1~R radioligands, including but not limited to \[^18^F\]FMSA4503[@bib21] (**2**), \[^18^F\]FPS[@bib22] (**3**), \[^18^F\]SFE[@bib23], [@bib24] (**4**), and \[^18^F\]FTC-146[@bib25] (**5**). Although most of them have been studied in human researches, and \[^18^F\]FTC-146 have completed early phase I trial of PET/MRI in healthy volunteers, and in complex regional pain syndrome (CRPS) and sciatica[@bib26], [@bib27], still each of them have unmet requirements and needs further investigation for practical clinic translation.

In our previous work, we identified 6-hydroxypyridazinone class of compounds with high *σ*~1~R affinity and high selectivity over *σ*~2~R[@bib28]. *Ex vivo* tests suggested comp-54 (**6**) of 6-hydroxypyridazinone derivatives were reported as the most promising candidate of high binding affinity (*σ*~1~R *K*~i~=1.4 nmol/L) and apparent good selectivity (*σ*~2~/*σ*~1~=1365.7). The pharmacological test of *in vivo* evaluation in rodent showed it was a *σ*~1~R antagonist and could possibly penetrate the blood‒brain barrier (BBB), and get into the *σ*~1~R-expressed region in mice brain, which exerted a highly potency of modified into *σ*~1~R radioligand for brain PET imaging. Aiming to preserve this high affinity and selectivity, we devised a strategy to modify **6** in ways that would incorporate a carbon-11 radiolabel without greatly altering the original framework of 6-hydroxypyridazinone in the target molecules.

To the best of our knowledge, no similar compounds with 6-hydroxypyridazinone scaffold have been developed as *σ*~1~R PET radiotracer. Since the core structure is distinct from existing PET radioligands for *σ*~1~R imaging, it could expand the diversity of available probes and facilitate future advances in a *σ*~1~R imaging. Here, we report the radiosynthesis of two novel carbon-11-labeled *σ*~1~R radioligands, \[^11^C\]HCC0923 and \[^11^C\]HCC0929, and demonstrate the *in vivo* pharmacokinetic properties, biodistribution of brain regions and major organs through PET/CT imaging for *σ*~1~R in the mice.

2. Results and discussion {#sec2}
=========================

2.1. Chemical synthesis {#sec2.1}
-----------------------

The chemical synthesis of the compounds **13--15** was illustrated in [Scheme 1](#sch1){ref-type="fig"}. The 6-hydroxypyridazinone derivatives were prepared following our previously reported work with minor changes[@bib28], [@bib29].Scheme 1Synthesis of 6-hydroxypyridazinone derivatives. Reagents and conditions: (a) maleic anhydride, H~2~O, conc. HCl, 100 °C, 8 h; (b) Br(CH~2~)~3~Br, K~2~CO~3~, acetone, 58 °C, 4 h; (c) Cs~2~CO~3~, acetonitrile, 62 °C, 2 h.Scheme 1

Briefly, through a one-step cyclization reaction of substitute phenylhydrazine hydrochloride and maleic anhydride, the intermediates **9** and **10** were prepared as white solid; Next, standard alkylation with 1,3-dibromopropane in acetone using potassium carbonate (K~2~CO~3~) was conducted to produce **11** and **12**, and then reacted with the piperidine, *tert*-butyl piperazine-1-carboxylate or 1-methylpiperazine respectively in the presence of cesium carbonate (Cs~2~CO~3~) in acetonitrile to afford the compound **13--15** in moderate yields.

2.2. Preparation of the precursors and radiosynthesis of \[^11^C\]HCC0923 and \[^11^C\]HCC0929 {#sec2.2}
----------------------------------------------------------------------------------------------

The preparation of the precursors **P1** and **P2** were using straightforward methods, as presented in [Scheme 2](#sch2){ref-type="fig"}. For precursor **P1**, the methoxy group in compound **13** was turned to hydroxy group by demethylation of BBr~3~ in ‒78 °C[@bib30]. For precursor **P2**, the *tert*-butyl ester in compound **14** was hydrolyzed in the presence of HCl solution in diethyl ether (2 mol/L) to form the designed precursor.Scheme 2Synthesis of radiolabeling precursor **P1** (16), **P2** (17) and radiosynthesis of \[^11^C\]HCC0923 and \[^11^C\]HCC0929. Reagents and conditions: (a) BBr~3~, dichloromethane, ‒78 °C to room temperature, overnight; (b) NaOH, DMF, 120 °C, 3 min; (c) 2 mol/L HCl in diethyl ether, dichloromethane, room temperature, overnight; (d) K~2~CO~3~, DMF, 120 °C, 3 min.Scheme 2

Two carbon-11-labeled radioligands were prepared through a standard methylation method, under the catalyzation of different bases, respectively. \[^11^C\]HCC0923 was prepared through precursor **P1** with \[^11^C\]CH~3~I. \[^11^C\]CH~3~I was produced from cyclotron and then trapped in a sealed vial with the precursor in DMF solution in the presence of sodium hydroxide (NaOH) followed by heating at 120 °C for 3 min. The reaction was consequently quenched with water and purified by semipreparative HPLC. Including formulation, \[^11^C\]HCC0923 was prepared in 35--40 min after the end of bombardment with adequate radiochemical yields (6%‒15%, uncorrected for decay and based on trapped \[^11^C\]CH~3~I) and high radiochemical purity (\>95%).

The procedure for synthesis of \[^11^C\]HCC0929 was almost the same as \[^11^C\]HCC0923, except using precursor **P2** with K~2~CO~3~ as the base catalyst instead of NaOH. The entire preparation including formulation takes approximately 35--40 min, with the radiochemical yields of 3%‒8% (uncorrected for decay and based on trapped \[^11^C\]CH~3~I) and radiochemical purity over 95%.

2.3. Ex vivo σ~1~R binding affinity, selectivity and logD of compounds **13** and **15** {#sec2.3}
----------------------------------------------------------------------------------------

An essential property of developing binding-based radiotracer is the binding potential (BP), which is usually represented as the ratio of receptor\'s density (*B*~max~) to binding affinity. A radiotracer which is suitable for quantitative comparisons with PET imaging has at least a value of BP over 5, especially in clinical investigation; in a non-research clinical setting, BP should typically be greater than 10[@bib31].

The *B*~max~ of *σ*~1~R in human brain was measured to be approximately 30‒600 fmol/mg (3‒60 nmol/L)[@bib32], [@bib33]. Thus, the radioligand with affinity of 0.6‒12 nmol/L could be used for *σ*~1~R imaging, and range of 0.3‒6 nmol/L will be more suitable. The *ex vivo σ*~1~R binding affinity of unlabeled HCC0923 (compound **13**) and HCC0929 (compound **15**) were measured through previously demonstrated methods (as described in [Supporting Information](#appsec1){ref-type="sec"})[@bib28], [@bib29]. The *σ*~1~R binding affinities of **13** and **15** were 10.3 and 5.6 nmol/L, with the selectivities of 111.3- and 272.8-fold to *σ*~2~R, respectively ([Table 1](#tbl1){ref-type="table"}[@bib13], [@bib27]). Compared to the most promising compound **6**, both **13** and **15** showed a slight decrease of *σ*~1~R binding affinity and selectivity, due to structure modifications necessary for radiolabeling; however, based on the criteria mentioned above, **13** and **15** still possessed suitable affinities for *in vivo* PET imaging of *σ*~1~R.Table 1*Ex vivo* binding affinities for *σ*~1~R and *σ*~2~R of PD 144418, compounds **6**, **13** and **15**.Table 1Compd.*σ*~1~R\
*K*~d~ or *K*~i~ (nmol/L)*σ*~2~R\
*K*~i~ (nmol/L)Selectivity\
(*σ*~2~R/*σ*~1~R)PD 144418[@bib13]4.3 ± 0.11377 ± 179--**6**[@bib27]1.4 ± 0.11912 ± 2101365.7**13**10.3 ± 1.11146 ± 116111.3**15**5.6 ± 0.71528 ± 120272.8[^1]

Besides the binding affinity and selectivity to the target receptor, the log*D* is also another important parameter, especially for the radiotracer for brain imaging. The experimental log*D*~PBS,pH7.4~±SD of compounds **13** and **15** were measured[@bib34] to be 0.89±0.06 and 1.73±0.08, respectively.

2.4. Molecular docking studies of 6-hydroxypyridazinone derivatives {#sec2.4}
-------------------------------------------------------------------

To predict the possible binding mode of the two radioligands, we performed molecular docking with Schrödinger Glide software (Schrödinger, LLC, New York, NY, USA) using the 2.5 Å resolution structure of the *σ*~1~R bound to PD 144418, in a similar manner as reported previously[@bib13], [@bib14], [@bib35].

Encouragingly, the top-ranked docked pose of PD 144418 in [Fig. 2](#fig2){ref-type="fig"}A (yellow) was nearly identical to that seen in the crystal structure ([Fig. 2](#fig2){ref-type="fig"}A, cyan), and the Glide score was comparable to what has been reported previously for high-affinity *σ*~1~R ligands[@bib13], [@bib14], [@bib35].Figure 2Glide docking of compounds into the *σ*~1~R (PDB 5HK1). (A) Pose of co-crystallized PD 144418 (pale cyan) and top-ranked pose from Glide docking (yellow). Best docked poses for (B) compound **6** (periwinkle), (C) compound **13** (cyan), (D) compound **15** (gold). In all panels, the receptor is shown in gray.Figure 2

The reference compound **6**, along with **13** and **15**, was docked in the same way. All three compounds adopted similar conformations in the ligand-binding site as PD 144418, with good Glide Scores ([Table 2](#tbl2){ref-type="table"}). Like all ligands co-crystallized with the receptor to date, the poses for compounds **6**, **13**, and **15** featured an electrostatic interaction between the positively charged nitrogen in the ligand and E172 ([Table 2](#tbl2){ref-type="table"}, [Fig. 2](#fig2){ref-type="fig"}B‒D). Additionally, as reported for all currently co-crystallized *σ*~1~R antagonists[@bib13], [@bib14], the primary hydrophobic regions of these compounds were positioned near Y203, pointing towards the membrane, and the secondary hydrophobic regions were pointing towards the bottom of the ligand binding site past D126. These results suggest that these compounds likely bind the receptor similarly to other high-affinity *σ*~1~R ligands.Table 2Distance of the electrostatic interaction between ligand\'s basic amine and E172, with Glide scores of PD 144418, HCC0923 and HCC0929 in molecular docking.Table 2Compd.Distance to E172 (Å)Glide Score (kcal/mol)PD 144418 (co-crystallized)3.1--PD 144418 (docking)3.1‒10.460**6**3.0‒10.251**13**2.7‒10.578**15**3.1‒10.577[^2]

*2.5*. *In vivo PET-CT imaging with \[*^*11*^*C\]HCC0923 in mice*[@bib36], [@bib37] {#sec2.5}
-----------------------------------------------------------------------------------

Following the encouraging data in *ex vivo σ*~1~R binding assays and molecular docking, two radioligands, \[^11^C\]HCC0923 and \[^11^C\]HCC0929, were a step forward to further *in vivo* investigation.

We firstly assessed \[^11^C\]HCC0923 *in vivo* conducting dynamic PET imaging focused on mice brains. In PET-CT studies, \[^11^C\]HCC0923 exerted high BBB penetration and fast uptake when administered by intravenous bolus injection (100‒150 μCi per animal), as shown in [Fig. 3](#fig3){ref-type="fig"}. Based on a whole-brain analysis, the concentration of \[^11^C\]HCC0923 in the mice brain reached a maximum uptake of 6.48% ID/cc within the first few minutes after injection, and sustained binding over the scanning time (60 min).Figure 3Mice brain PET/CT images 25‒60 min after intravenous administration (i.v.) of radioligand \[^11^C\]HCC0923 and time‒activity curve. (A) Baseline PET/CT image. (B) and (C) PET/CT image from blocking study, involving i.v. pretreatment with unlabeled HCC0923 (self-blocking, B: 1.25 mg/kg, C: 12.5 mg/kg) 5.0 min before radioligand injection. (D) Time‒activity curve demonstrating uptake of radiolingand for baseline and blocking studies (low & high dose).Figure 3

To investigate the specificity of \[^11^C\]HCC0923, we performed PET imaging studies in mice with a 5-min pretreatment of compound **13** (unlabeled HCC0923) at different doses (1.25 and 12.5 mg/kg). Compared with the non-pretreat control (baseline, [Fig. 3](#fig3){ref-type="fig"}A), we found that the \[^11^C\]HCC0923 binding in mice brain was blocked in a dose-dependent manner with a stepwise reduction in the percent tracer uptake after administration of **13** ([Fig. 3](#fig3){ref-type="fig"}B and C). At 1.25 mg/kg, we found an approximate 38% reduction in binding, estimated as the percent change in whole-brain radioactivity between peak uptake at 10 min and the lowest uptake at 60 min. Increasing the dose of **13** to 12.5 mg/kg resulted in a ∼54% reduction in \[^11^C\]HCC0923 brain uptake, a dose-dependent response to self-blockade and ∼45% of uptake attributed to non-specific binding. We observed a similar blockade level at the last 10 min, indicating saturation at 1.25 mg/kg. This finding demonstrates a high specific binding of \[^11^C\]HCC0923 for *σ*~1~R, with a dose-dependent response to self-blockade.

*2.6*. *In vivo PET-CT imaging with \[*^*11*^*C\]HCC0929 in mice*[@bib36], [@bib37] {#sec2.6}
-----------------------------------------------------------------------------------

\[^11^C\]HCC0929 was also studied in mice PET-CT imaging due to its better *σ*~1~R affinity. To test \[^11^C\]HCC0929 as a radiotracer *in vivo*, we conducted PET imaging focused on the mice brains. Compared to \[^11^C\]HCC0923, we determined that \[^11^C\]HCC0929 exhibited more potent properties in PET imaging studies: higher BBB penetration and faster signal decrease over the 60-min scan when administered by intravenous bolus injection (100‒150 μCi per animal), as shown in [Fig. 4](#fig4){ref-type="fig"}.Figure 4Mice brain PET/CT images 25‒60 min after intravenous administration (i.v.) of radioligand \[^11^C\]HCC0929 and time‒activity curve. (A) Baseline PET/CT image. (B) and (C) PET/CT image from blocking study, involving i.v. pretreatment with unlabeled HCC0929 (self-blocking, B: 0.288 mg/kg, C: 2.88 mg/kg) 5.0 min before radioligand injection. (D) Time‒activity curve demonstrating uptake of radioligand for baseline and blocking studies (low & high dose).Figure 4

Unlike the slow gradient of baseline curve of \[^11^C\]HCC0923, the whole-brain analysis that exerted the concentration of \[^11^C\]HCC0929 in the mice brain reached a maximum uptake of 7.66% ID/cc at ∼5 min after injection with moderate wash-out rate during the scanning period (60 min), indicating a faster brain clearance kinetic property compared to \[^11^C\]HCC0923. The specificity of \[^11^C\]HCC0929 was investigated in mice PET imaging studies with a 5-min i.v. pretreatment of compound **15** (unlabeled HCC0929) at doses of 0.288 and 2.88 mg/kg.

We found that administration of 0.288 mg/kg unlabeled HCC0929 (**15**) blocked \[^11^C\]HCC0929 binding in the mice brain by approximately 36%, measured as the percent change in whole radioactivity between peak uptake at ∼5 min and the lowest uptake at 60 min. Increasing the dose of **15** to 2.88 mg/kg resulted in a ∼58% reduction in \[^11^C\]HCC0929 mice brain uptake ([Fig. 4](#fig4){ref-type="fig"}D), which represents a dose-dependent response to self-blockade and ∼40% of uptake attributed to non-specific binding. The mice *in vivo* PET-CT studies demonstrated a high uptake and good mice brain clearance kinetic of \[^11^C\]HCC0929 for *σ*~1~R imaging in brain, with a dose-dependent response to self-blockade.

2.7. Positive ligands blocking study of *in vivo* PET-CT imaging using \[^11^C\]HCC0929 in mice {#sec2.7}
-----------------------------------------------------------------------------------------------

To further validate the selectivity of *σ*~1~R of the candidate radioligand \[^11^C\]HCC0929, two highly *σ*~1~R selective ligands, SA 4503 (*σ*~1~R agonist) and PD 144418 (*σ*~1~R antagonist) were adopted for positive ligands blocking study[@bib36], [@bib37].

Through the *in vivo* PET-CT imaging in mice brain ([Fig. 5](#fig5){ref-type="fig"}), we found that administration of SA 4503 (2.75 mg/kg) or PD 144418 (2.99 mg/kg) could remarkably reduce the \[^11^C\]HCC0929 binding in the mice brain by approximately 41% and 67%, respectively, measured as the percent change in whole radioactivity between peak uptake at ∼5 min and the lowest uptake at 60 min. The different blocking effects of two positive ligands might due to their entirely opposite functional profiles. The shape of time‒active curve of self-blocking was close to the curve of PD 144418, since the compound **15** acted as the same as antagonist, but the binding affinity to *σ*~1~R was a little higher than PD 144418.Figure 5Mice brain PET/CT images 25‒60 min after intravenous administration (i.v.) of radioligand \[^11^C\]HCC0929 and time‒activity curve. (A) Baseline PET/CT image (*n*=2); PET/CT image from blocking study, involving i.v. pretreatment with positive compounds 5.0 min before radioligand injection: (B) unlabeled HCC0929 (self-blocking, 2.88 mg/kg); (C) SA 4503 (*σ*~1~R agonist, 2.75 mg/kg); (D) PD 144418 (*σ*~1~R agonist, 2.99 mg/kg); (E) Time‒activity curve demonstrating uptake of radioligand for baseline and blocking studies (low & high dose).Figure 5

2.8. In vivo biodistribution studies of \[^11^C\]HCC0929 in mice {#sec2.8}
----------------------------------------------------------------

The biodistribution of radioligand \[^11^C\]HCC0929 in mice was investigated by *in vivo* PET-CT imaging, and the data were acquired by using the FUSION module in PMOD (PMOD 4.003, PMOD Technologies Ltd., Zurich, Switzerland).

The analysis of detailed distribution of different brain regions of mice was obtained through the mouse (Ma-Benveniste-Mirrione) VOI atlas[@bib38], [@bib39]. Eight important functional regions of mice brain were selected: cortex, cerebellum, brain stem, thalamus, hypothalamus, striatum, hippocampus and amygdala. The radioligand \[^11^C\]HCC0929 distributed in the selected brain regions were investigated and showed quite similar distribution patterns[@bib40] without significant regional differences ([Fig. 6](#fig6){ref-type="fig"}). In blocking studies, the uptake of \[^11^C\]HCC0929 in different regions of mice brain was significantly decreased by co-injection of HCC0929. In high dose injection (2.88 mg/kg), all the selected brain regions of mice were decreased significantly as the same; while pretreated a low dose of HCC0929 (0.288 mg/kg), the cortex, striatum and hippocampus showed a moderate decrease compared to other mice brain regions, which were mainly because of the different express of *σ*~1~R in these regions.Figure 6Time-activity curve demonstrating uptake of radioligand \[^11^C\]HCC0929 for baseline and blocking studies (self-blocking, low blocking dose: 0.288 mg/kg, high blocking dose: 2.88 mg/kg) of different brain regions of mice brain, including cortex, cerebellum, brain stem, thalamus, hypothalamus, striatum, hippocampus, amygdala.Figure 6

The distribution of major organs in mice was analyzed using the PBAS module in PMOD 4.003. The mean radioactive uptake in brain and major organs at each time point is showed in [Fig. 7](#fig7){ref-type="fig"}. The highest uptake occurred at 5 min in brain (7.66±0.82% ID/cc), heart (5.10±0.68% ID/cc), lung (6.75±0.86% ID/cc) and kidney (8.87±1.16% ID/cc), and then the radioligand was gradually washed out from these organs. Whereas in liver and spleen, due to the accumulation of \[^11^C\]HCC0929, the time point of maximum uptake was behind other organs. The uptake in liver peaked at 30 min at 14.70±2.03% ID/cc and slightly decreased in 60 min; in spleen, the maximum radioactivity uptake reached in 15 min at 13.32±2.03% ID/cc and then was slowly washed out during study.Figure 7Biodistribution of radioligand \[^11^C\]HCC0929 in rats at 5, 15, 30, and 60 min after injection of radioligand (*n*=3 for each time point). Error bars represent SEM.Figure 7

3. Conclusions {#sec3}
==============

In summary, two novel carbon-11 labeled *σ*~1~R radioligands with a 6-hydroxypyridazinone scaffold, \[^11^C\]HCC0923 and \[^11^C\]HCC0929, were successfully prepared and evaluated in mice. Both two radioligands can highly bind to *σ*~1~R in the mice brain, with good selectivity and specificity. Of the two novel ^11^C-labeled sigma-1 receptor radioligands, \[^11^C\]HCC0929 possessed better kinetic property and specificity which was further investigated in positive ligands blocking studies in mice PET-CT brain imaging, using classic *σ*~1~R agonist SA 4503 and *σ*~1~R antagonist PD 144418. Both *σ*~1~R ligands could extensively decreased the uptake of \[^11^C\]HCC0929 in mice brain, with different kinetic uptake and washout properties. Besides, the biodistribution of major brain regions and organs of mice were determined *in vivo*. The radioligand \[^11^C\]HCC0929 distributed in the selected brain regions showed quite similar distribution patterns as reported, and the distribution in major organs extent the good pharmacokinetic properties *in vivo*. These results demonstrated its promise as preclinical tools for visualizing and quantitating *σ*~1~R density in the mice brain *in vivo*.

Application \[^11^C\]HCC0929 as PET probes could be used to quantify *σ*~1~R expression in various neurological disorders, and would also be valuable for evaluation of potential drugs in living subjects. The approach is also valuable for expanding the variety and diversity of PET radiotracers for *σ*~1~R imaging to meet the requirements for practical clinic application and therefore warrants further investigation.

4. Experimental {#sec4}
===============

4.1. General methods and materials {#sec4.1}
----------------------------------

All commercially available chemical reagents and solvents were of ACS-grade purity or higher, and used without further purification.

^1^H NMR and ^13^C NMR spectra data were recorded on a JEOL JNM-ECZ500R Spectrometer (JEOL Ltd, Tokyo, Japan) at 500 MHz (^1^H) and 126 MHz (^13^C) using chloroform-*d*. Chemical shifts were given in *δ* values (ppm), using tetramethylsilane (TMS) as the internal standard; coupling constants (*J*) were given in Hz. Signal multiplicities were characterized as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad signal).

Analytical thin layer chromatography (TLC) was performed on silica gel GF254. Column chromatographic purification was carried out using silica gel. Analytical separation was conducted on an Agilent 1100 series HPLC (Agilent Technologies, Inc., Santa Clara, CA, USA) fitted with a diode-array detector, quaternary pump, vacuum degasser, and autosampler. Mass spectrometry data were recorded on an Agilent 6310 ion trap mass spectrometer (ESI source, Agilent Technologies, Inc., Santa Clara, CA, USA) connected to an Agilent 1200 series HPLC with quaternary pump, vacuum degasser, diode-array detector, and autosampler.

\[^11^C\]CO~2~ (1.2 Ci) was obtained *via* the ^14^N (*p, α*) ^11^C reaction on nitrogen with 2.5% oxygen, with 11 MeV protons (Siemens Eclipse cyclotron, Siemens Healthcare GmbH, Erlangen, Germany), and trapped on molecular sieves in a TRACERlab FX-MeI synthesizer (General Electric, GE Healthcare, Boston, MA, USA). \[^11^C\]CH~4~ was obtained by the reduction of \[^11^C\]CO~2~ in the presence of Ni/hydrogen at 350 °C and recirculated through an oven containing I~2~ to produce \[^11^C\]CH~3~I *via* a radical reaction.

All animal studies were carried out at Massachusetts General Hospital (MGH, PHS Assurance of Compliance No. A3596-01). The Subcommittee on Research Animal Care (SRAC) serves as the Institutional Animal Care and Use Committee (IACUC) for the Massachusetts General Hospital. SRAC reviewed and approved all procedures detailed in this paper.

Micro PET-CT imaging was performed in anesthetized (isoflurane) mice (BALB/c) to minimize discomfort. Highly trained animal technicians monitored animal safety throughout all procedures, and veterinary staff were responsible for daily care. All mice were socially housed in cages appropriate for the physical and behavioral health of the individual animal and were given unlimited access to food and water, with additional nutritional supplements provided as prescribed by the attending veterinary staff.

4.2. Chemical synthesis {#sec4.2}
-----------------------

### 4.2.1. General procedure for the preparation of intermediates **9** and **10** {#sec4.2.1}

*6-Hydroxy-2-(4-methoxyphenyl)pyridazin-3(2H)-one (****9****).* To a mixture of (4-methoxyphenyl)hydrazine hydrochloride (**7**, 55 mmol) and maleic anhydride (50 mmol) in H~2~O (400 mL), concentrated hydrochloric acid solution (40 mL) was added slowly with stirring. The mixture was heated at 120 °C for 8 h. The progress of the reaction was monitored by TLC. After cooling to room temperature and filtrating, the resulting solid was washed with ice‒water and dissolved in a saturated sodium bicarbonate solution. After another filtration, the resulting filtrate was neutralized with 1 mol/L hydrochloric acid and formed a precipitate. The precipitate was then filtered and washed with water to yield 6-hydroxy-2-(4-methoxyphenyl)pyridazin-3(2*H*)-one, **9**, as a white solid (7.22 g, 66.2%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.49 (d, *J*=8.7 Hz, 2H), 7.10--7.02 (m, 2H), 7.00--6.94 (m, 2H), 3.84 (s, 3H). A signal for the OH-proton is not visible. LC--MS Calcd. for C~11~H~10~N~2~O~3~ expected \[M+H\]^+^: 219.1; Found \[M+H\]^+^: 219.1.

*2-(3,4-Dichlorophenyl)-6-hydroxypyridazin-3(2H)-one (****10****).* The procedure described for the synthesis of **9** was applied to the initial compound **8** (55 mmol), maleic anhydride (50 mmol), and H~2~O (400 mL) with concentrated HCl solution (40 mL) to afford 2-(3,4-dichlorophenyl)-6-hydroxypyridazin-3(2*H*)-one, **10** as a white solid (9.01 g, 70.1%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.89 (d, *J*=2.3 Hz, 1H), 7.65 (dd, *J*=8.7, 2.5 Hz, 1H), 7.52 (d, *J*=8.8 Hz, 1H), 7.01 (s, 2H). A signal for the OH-proton is not visible. LC--MS Calcd. for C~10~H~6~Cl~2~N~2~O~2~ expected \[M+H\]^+^: 258.1; Found \[M+H\]^+^: 258.1.

### 4.2.2. General procedure for the preparation of intermediates **11** and **12** {#sec4.2.2}

*6-(3-Bromopropoxy)-2-(4-methoxyphenyl)pyridazin-3(2H)-one (****11****).* To a solution of **9** (10 mmol) and 1,3-dibromopropane (20 mmol) in acetone (100 mL), potassium carbonate (20 mmol) was added and the mixture was refluxed for 4 h. The progress of the reaction was monitored by TLC. After cooled to room temperature, the mixture was filtered and the solvent was evaporated under reduced pressure. The crude product was purified by means of flash chromatography (hexane/ethyl acetate=50/1) to yield 6-(3-bromopropoxy)-2-(4-methoxyphenyl)pyridazin-3(2*H*)-one, **11**, as a pale-yellow oil (1.89 g, 55.6%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.57 (d, *J*=8.8 Hz, 2H), 7.06--7.01 (m, 2H), 7.00--6.95 (m, 2H), 4.31 (t, *J*=5.9 Hz, 2H), 3.84 (s, 3H), 3.55 (t, *J*=6.4 Hz, 2H), 2.30 (p, *J*=6.2 Hz, 2H). ^13^C NMR (126 MHz, chloroform-*d*) *δ* 158.89, 152.50, 134.68, 134.08, 126.56, 126.36, 113.96, 64.80, 55.62, 31.75, 29.61. LC--MS Calcd. for C~14~H~15~BrN~2~O~3~ expected \[M+H\]^+^: 340.2; Found \[M+H\]^+^: 340.1.

*6-(3-Bromopropoxy)-2-(3,4-dichlorophenyl)pyridazin-3(2H)-one (****12****).* The procedure described for the synthesis of **11** was applied to intermediate **10** (10 mmol), 1,3-dibromopropane (20 mmol), and potassium carbonate (20 mmol) in acetone (100 mL) to afford 6-(3-bromopropoxy)-2-(3,4-dichlorophenyl)pyridazin-3(2*H*)-one, **12** as a light yellow oil (1.97 g, 52.0%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.88 (d, *J*=2.3 Hz, 1H), 7.64 (dd, *J*=8.7, 2.5 Hz, 1H), 7.51 (d, *J*=8.8 Hz, 1H), 7.00 (s, 2H), 4.33 (t, *J*=5.9 Hz, 2H), 3.56 (t, *J*=6.5 Hz, 2H), 2.32 (p, *J*=6.2 Hz, 2H). ^13^C NMR (126 MHz, chloroform-*d*) *δ* 158.55, 152.77, 140.63, 134.34, 132.58, 131.48, 130.23, 127.23, 126.70, 124.09, 65.01, 31.62, 29.47. LC--MS Calcd. for C~13~H~11~BrCl~2~N~2~O~2~ expected \[M+H\]^+^: 379.1; Found \[M+H\]^+^: 379.1.

### 4.2.3. General procedure for the preparation of compounds **13** to **15** {#sec4.2.3}

*2-(4-Methoxyphenyl)-6-(3-(piperidin-*1-yl*)propoxy)pyridazin-3(2H)-one (****13****).* A mixture of intermediate **11** (5 mmol) and piperidine (5.5 mmol) in acetonitrile (50 mL) and cesium carbonate (10 mmol) was heated and refluxed for 2 h. After filtering, the resulting filtrate was evaporated to dryness under reduced pressure. The residue was suspended in water (50 mL) and extracted with dichloromethane (3 × 25 mL). The combined organic layers were dried with anhydrous magnesium sulfate, the filtrate was evaporated under reduced pressure, and the crude product was purified by means of flash chromatography (CH~2~Cl~2~/CH~3~OH=10/1) to yield 2-(4-methoxyphenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2*H*)-one, **13**, as a yellow oil (1.46 g, 84.8%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.56 (d, *J*=8.7 Hz, 2H), 7.03--6.93 (m, 4H), 4.19 (t, *J*=6.4 Hz, 2H), 3.84 (s, 3H), 2.53--2.30 (m, 6H), 1.96 (p, *J*=6.7 Hz, 2H), 1.60 (p, *J*=5.6 Hz, 4H), 1.51--1.40 (m, 2H). ^13^C NMR (126 MHz, chloroform-*d*) *δ* 158.91, 158.81, 152.79, 134.81, 133.89, 126.79, 126.38, 113.93, 65.86, 55.98, 55.61, 54.67, 26.23, 25.90, 24.40. LC--MS Calcd. for C~19~H~25~N~3~O~3~ expected \[M+H\]^+^: 344.2; Found \[M+H\]^+^: 344.2, HR-MS Calcd. for C~19~H~25~N~3~O~3~ expected \[M+H\]^+^: 344.1964; Found \[M+H\]^+^: 344.1969.

*tert-Butyl 4-(3-((1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-*3-yl*)oxy)-propyl)piperazine-1-carboxylate (****14****).* The procedure described for the synthesis of **13** was applied to intermediate **12** (5 mmol), *tert*-butyl piperazine-1-carboxylate (5.5 mmol), and cesium carbonate (10 mmol) in acetonitrile (50 mL) to afford 4-(3-((1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-propyl)piperazine-1-carboxylate, **14** as a light yellow oil (1.78 g, 73.5%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.87 (d, *J*=2.5 Hz, 1H), 7.64 (dd, *J*=8.8, 2.4 Hz, 1H), 7.51 (d, *J*=8.8 Hz, 1H), 6.99 (s, 2H), 4.23 (t, *J*=6.4 Hz, 2H), 3.44--3.30 (m, 4H), 2.50 (t, *J*=7.3 Hz, 2H), 2.45--2.34 (m, 4H), 1.96 (p, *J*=6.7 Hz, 2H), 1.46 (s, 9H). ^13^C NMR (126 MHz, chloroform-*d*) *δ* 158.59, 153.05, 140.74, 134.13, 132.53, 131.38, 130.18, 127.49, 126.72, 124.13, 65.88, 55.11, 55.04, 53.18, 46.05, 26.16. LC--MS Calcd. for C~22~H~28~Cl~2~N~4~O~4~ expected \[M+H\]^+^: 484.4; Found \[M+H\]^+^: 484.3.

*2-(3,4-Dichlorophenyl)-6-(3-(4-methylpiperazin-*1-yl*)propoxy)pyridazin-3(2H)-one (****15****).* The procedure described for the synthesis of **13** was applied to intermediate **12** (5 mmol), 1-methylpiperazine (5.5 mmol), and cesium carbonate (10 mmol) in acetonitrile (50 mL) to afford 2-(3,4-dichlorophenyl)-6-(3-(4-methylpiperazin-1-yl)propoxy) pyridazin-3(2*H*)-one, **15** as a light yellow oil (1.60 g, 80.6%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.87 (d, *J*=2.4 Hz, 1H), 7.64 (dd, *J*=8.7, 2.4 Hz, 1H), 7.50 (d, *J*=8.7 Hz, 1H), 6.99 (s, 2H), 4.22 (t, *J*=6.4 Hz, 2H), 2.62--2.40 (m, 10H), 2.31 (s, 3H), 1.96 (p, *J*=6.7 Hz, 2H). ^13^C NMR (126 MHz, chloroform-*d*) *δ* 158.57, 154.80, 153.03, 140.72, 134.16, 132.53, 131.39, 130.18, 127.45, 126.70, 124.11, 79.76, 65.76, 55.11, 55.04, 53.10, 28.51, 26.07. LC--MS Calcd. for C~18~H~22~Cl~2~N~4~O~2~ expected \[M+H\]^+^: 396.1; Found \[M+H\]^+^: 397.2, HR-MS Calcd. for C~18~H~22~Cl~2~N~4~O~2~ expected \[M+H\]^+^: 397.1193; Found \[M+H\]^+^: 397.1190.

*2-(4-Hydroxyphenyl)-6-(3-(piperidin-*1-yl*)propoxy)pyridazin-3(2H)-one (****16****, precursor* ***P1****)* Under N~2~, a solution of **13** (1 mmol) in dichloromethane (14 mL) was kept in an acetone-dry ice bath at ‒78 °C. 6 mL of Boron tribromide solution (1.0 mol/L in dichloromethane) was added carefully to the stirring solution and kept at ‒78 °C for 2 h. As the solution of boron tribromide was added, a pale yellow precipitate formed. The reaction mixture was gradually warmed to room temperature and kept stirring overnight. The reaction mixture was then hydrolyzed by careful shaking with 40 mL of H~2~O, thus precipitating a white solid, which was dissolved by the addition of 30 mL of dichloromethane. The organic layer was separated and extracted with 20 mL of 2 mol/L sodium hydroxide; the alkaline extract was neutralized with dilute hydrochloric acid and extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried with anhydrous magnesium sulfate, the filtrate was evaporated under reduced pressure, and the crude product was purified by means of flash chromatography (CH~2~Cl~2~/CH~3~OH=10/1) to yield 2-(4-hydroxyphenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2*H*)-one (**16,** precursor **P1**) as a pale yellow oil (0.142 g, 43.2%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.32 (d, *J*=8.5 Hz, 2H), 7.00--6.91 (m, 2H), 6.84--6.73 (m, 2H), 4.17 (t, *J*=6.2 Hz, 2H), 3.00--2.44 (m, 6H), 2.08 (t, *J*=7.5 Hz, 2H), 1.82--1.66 (m, 4H), 1.59--1.41 (m, 2H). A weak signal for the Ar--OH--proton is in *δ* 8.04, hardly visible. ^13^C NMR (126 MHz, chloroform-*d*) *δ* 159.17, 156.92, 152.77, 133.59, 133.39, 126.89, 126.53, 115.74, 65.32, 55.57, 54.22, 25.02, 24.61, 23.52. LC--MS Calcd. for C~18~H~23~N~3~O~3~ expected \[M+H\]^+^: 330.2; Found \[M+H\]^+^: 330.2, HR-MS Calcd. for C~18~H~23~N~3~O~3~ expected \[M+H\]^+^: 330.1812; Found \[M+H\]^+^: 330.1813.

*2-(3,4-Dichlorophenyl)-6-(3-(piperazin-*1-yl*)propoxy)pyridazin-3(2H)-one (****17****, precursor* ***P2****)* Under N~2~, a solution of **14** (1 mmol) in dichloromethane (18 mL) was kept in an ice bath at 0 °C. 2 mL of hydrogen chloride solution (1.0 mol/L in diethyl ether) was added to the stirring solution. As the solution of hydrogen chloride was added, a pale yellow precipitate was formed. The reaction mixture was gradually warmed to room temperature and kept stirring overnight. After that, the reaction mixture was neutralized by 30 mL of saturated sodium bicarbonate solution and extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried with anhydrous magnesium sulfate, the filtrate was evaporated under reduced pressure, and the crude product was purified by means of flash chromatography (CH~2~Cl~2~/CH~3~OH=10/1) to yield 2-(3,4-dichlorophenyl)-6-(3-(piperazin-1-yl)propoxy)pyridazin-3(2*H*)-one (**17,** precursor **P2**) as a yellow oil (0.353 g, 92.1%). ^1^H NMR (500 MHz, chloroform-*d*) *δ* 7.86 (d, *J*=2.4 Hz, 1H), 7.63 (dd, *J*=8.8, 2.4 Hz, 1H), 7.51 (d, *J*=8.7 Hz, 1H), 7.03--6.95 (m, 2H), 4.22 (t, *J*=6.4 Hz, 2H), 3.25--3.16 (m, 2H), 3.09--2.40 (m, 9H), 2.09--1.89 (m, 2H). ^13^C NMR (126 MHz, chloroform-*d*) *δ* 158.54, 152.93, 134.27, 134.19, 130.24, 130.20, 127.42, 127.34, 126.72, 124.14, 65.31, 54.58, 50.08, 43.80, 25.88. LC--MS Calcd. for C~17~H~20~Cl~2~N~4~O~2~ expected \[M+H\]^+^: 383.1; Found \[M+H\]^+^: 383.1, HR-MS Calcd. for C~17~H~20~Cl~2~N~4~O~2~ expected \[M+H\]^+^: 383.1036; Found \[M+H\]^+^: 383.1032.

4.3. Radiosynthesis {#sec4.3}
-------------------

*\[*^*11*^*C\]HCC0923.* \[^11^C\]methyl iodide (\[^11^C\]CH~3~I) was trapped in a TRACERlab FX-M synthesizer reactor (General Electric) preloaded with a solution of precursor **P1** in anhydrous DMF (2.0 mg/mL, 0.3 mL) and NaOH (8 mg). The solution was stirred at 120 °C for 3 min, and 0.1% trifluoroacetic acid (TFA) in water (1.2 mL) was added. The reaction mixture was purified by reverse phase semipreparative HPLC (Agilent Eclipse XDB-C18, 5 μm, 250 mm × 9.4 mm, flow rate=5.0 mL/min, mobile phase=0.1% TFA in water/0.1% TFA in acetonitrile, 82/18, *v*/*v*), and the desired fraction was collected. The final product was reformulated by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H~2~0 (5 mL), eluting with DMSO (1 mL), and diluting with saline solution (0.9%, 9 mL).

The average time required for the synthesis from end of cyclotron bombardment to end of synthesis was approximate 40‒50 min. The average radiochemical yield was 6%−15% (nondecay corrected to trapped \[^11^C\]CH~3~I). Chemical and radiochemical purities were ≥95% with a specific activity 1.29±0.2 Ci/μmol (EOB).

*\[*^*11*^*C\]HCC0929.* \[^11^C\]methyl iodide (\[^11^C\]CH~3~I) was trapped in a TRACERlab FX-M synthesizer reactor (General Electric) preloaded with a solution of precursor **P2** in anhydrous DMF (2.0 mg/mL, 0.3 mL) and K~2~CO~3~ (8 mg). The solution was stirred at 120 °C for 3 min, and 0.1 mol/L ammonium formate (AF) in water (1.2 mL) was added. The reaction mixture was purified by reverse phase semipreparative HPLC (Phenomenex Luna 5u C8(2), 250 mm × 10 mm, 5 μm, flow rate=5.0 mL/min, mobile phase=0.1 mol/L AF in water/acetonitrile, 65/35, *v*/*v*), and the desired fraction was collected. The final product was reformulated by loading onto a solid-phase exchange (SPE) C-18 cartridge, rinsing with H~2~0 (5 mL), eluting with EtOH (1 mL), and diluting with saline solution (0.9%, 9 mL).

The average time required for the synthesis from end of cyclotron bombardment to end of synthesis was approximate 40‒50 min. The average radiochemical yield was 3%−8% (nondecay corrected to trapped \[^11^C\]CH~3~I). Chemical and radiochemical purities were ≥95% with a specific activity 1.62±0.2 Ci/μmol (EOB).

4.4. Molecular docking {#sec4.4}
----------------------

Molecular docking into the *σ*~1~R was performed in the manner of previous work[@bib13], [@bib14], [@bib35] with Glide 5.5 extra precision (XP) Maestro 11 Schrodinger software (Schrödinger, LLC, New York, NY, USA) release 2016--3[@bib41].

The 2.5 Å resolution structure of *σ*~1~R in complex with PD 144418 (PDB [5KH1](pdb:5KH1){#intref0010}) was used for docking, compared with the *ex vivo* binding affinity[@bib42]. Because the structure has three protomers in the asymmetric unit, only chain C was used for docking studies. Lipids, ions, and waters were removed before protein preparation, thus leaving only the protein and ligand. Hydrogen atoms were added, and the protein was further refined by assignment of hydrogen bonds and minimization of energy for the OPLS3 force field. The grid used for docking was centered on the location of the co-crystallized ligand PD 144418, and was 20 Å in the *x*, *y*, and *z* dimensions. Poses were ranked according to glide score and inspected visually. Only poses in which the ligand\'s basic amine made an electrostatic interaction with E172 were considered plausible, as this has been observed in all five existing *σ*~1~R crystal structures currently available[@bib13], [@bib14].

4.5. Mice PET-CT acquisition and post processing {#sec4.5}
------------------------------------------------

Male Balb/c mice were tested in groups, each group contained 4 mice, anesthetized with inhalational isoflurane (Patterson Vet Supply, Inc., Greeley, CO, USA) at 2% in a carrier of 2 L/min medial oxygen, and maintained at 1% isoflurane for the duration of the scan.

The mice were arranged side-by-side in two layers in a Triumph Trimodality PET/CT/SPECT scanner (Gamma Medica, Northridge, CA, USA). Mice were injected standard references or vehicle *via* a lateral tail vein catheterization at the start of PET acquisition. Dynamic PET acquisition lasted for 60 min followed by computed tomography (CT) for anatomic coregistration. PET data were reconstructed using a 3D-MLEM method resulting in a full width at half-maximum resolution of 1 mm. Reconstructed images were exported from the scanner in DICOM format along with an anatomic CT for rodent studies. These files were imported and analyzed using AMIDE (a medical imaging data examiner) software (an open-source software, Los Angeles, CA, USA)[@bib43] and PMOD (PMOD4.003, PMOD Technologies Ltd., Zurich, Switzerland).

4.6. Mice PET-CT image analysis {#sec4.6}
-------------------------------

Volumes of interest (VOIs) were generated manually in forms of spheres under the guide of high-resolution CT structural images and summed PET data in mice brain regions, with a radius no less than 1 mm to minimize partial volume effects. Time-activity curves (TACs) were exported as decay-corrected activity per unit volume. The TACs were expressed as percent injected dose per unit volume for analysis.
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